stockrowImmunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024.
- Revenue
- −1.42%
- EPS
- −7,900.0%
- Free cash flow
- +441.0%
- Total debt
- +0.55%
Quarter to September 2026, against a year earlier
Follow IMCR
Alert me
Immunocore Holdings PLC Sponsored ADR (IMCR) EV/Sales
As of 6 November 2026, Immunocore Holdings PLC Sponsored ADR (IMCR) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from 0.0× (June 2021) to 39.7× (November 2021); the current reading is higher than 11% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.3× | (6.06%) |
| FY2024 | 3.5× | (71.72%) |
| FY2023 | 12.5× | (0.34%) |
| FY2022 | 12.5× | (62.48%) |
| FY2021 | 33.3× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.6× | (6.22%) |
| Jun 2026 | 2.7× | 0.37% |
| Mar 2026 | 2.7× | (17.54%) |
| Dec 2025 | 3.3× | (8.88%) |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TYRA Tyra Biosciences, Inc. compare | n/m |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | n/m |
| IMCR Immunocore Holdings PLC Sponsored ADR | 2.6× |
| NUVB Nuvation Bio Inc. compare | 5.4× |
| PGEN Precigen, Inc. compare | 10.5× |
| OCUL Ocular Therapeutix, Inc. compare | 18.5× |
| QURE uniQure N.V. compare | 44.7× |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | 5,356× |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)